NZ clinical trial business P3 sells

NZ clinical trial business P3 sells
Staff reporters
Australian private equity investor Genesis Capital has purchased a majority stake in New Zealand clinical-trial business P3 Research.Sydney-based Genesis, a specialist healthcare investor, has paid to buy most of P3 Research, with managing director Richard Stubbs retaining an 11% stake. Genesis plans to invest $30 million to back P3's clinical growth trials on both sides of the Tasman. P3 has five sites across NZ and runs trials for international pharmaceutical companies as well as small-scale early trials. It is the largest provider i...